The celebrated annual release of abstracts from the American Society of Clinical Oncology (ASCO) meeting claimed an early victim Thursday as shares of Jounce Therapeutics Inc. (NASDAQ:JNCE) fell 35.2 percent, closing at $11.45 for a loss of $6.22, after analysts began sifting through the data dump and found the company's update wanting.